ADHD

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

A new study found stimulant use in children dropped 19% early in the pandemic but rebounded, with the 2022 Adderall shortage prompting shifts to alternatives.

The FDA approved updated labeling for viloxazine ER capsules as an ADHD treatment, adding lactation data and details on serotonin 5-HT2C receptor activity.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

Sibling control analyses showed acetaminophen use during pregnancy was not associated with an offspring’s risk of autism, ADHD, or intellectual disability.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.

Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.

In a new study, patients with ADHD on cannabis-based medicinal products had significant improvements for anxiety, sleep quality, and health-related quality of life.

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.

Adult ADHD is associated with a 2.77-fold increased risk of dementia, according to new research.

Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.

Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.